Treatment of High Altitude Polycythemia by Acetazolamide
Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The prevalence of High Altitude Polycythemia (or Chronic Mountain Sickness) is between 8 and
15% in the high altitude regions of South America. There is no pharmacological treatment
available. After a first preliminary study in 2003 demonstrating the beneficial effects of
acetazolamide in reducing hematocrit in these patients, after 3 weeks of treatment, we want
to confirm this effect and implement a treatment protocol of 3 month-duration.
Phase:
Phase 4
Details
Lead Sponsor:
Association pour la Recherche en Physiologie de l'Environnement
Collaborators:
Legs Poix Universidad Peruana Cayetano Heredia University of Paris 13